title: [Erb-2 overexpression in breast cancer].
abstract: Overexpression of the Erb B-2 receptor plays an important role in the pathogenesis of breast cancer. It results in the formation of heterodimers consisting of Erb-B2/Erb B-3 receptors which have an ability to produce stable and external factors independent mitotic stimuli. Together with an autocrine stimulation of neoplastic cell proliferation by heregulin and cyclooxygenase 2 activation it is a significant factor in carcinogenesis. Overexpression of Erb B-2 seems to be an independent negative prognostic factor in breast cancer. Its predictive value is not clear-cut. It is suggested that breast cancer showing Erb B-2 overexpression is more sensitive to treatment with anthracyclines and less to CMF. The anti-Erb B-2 monoclonal antibody (trastuzumab) is used in treatment of metastatic breast cancer both as a single drug and in combination with chemotherapy.
authors.affiliation: Kliniki Chorób Wewnetrznych 4 Wojskowego Szpitala Klinicznego z Poliklinika we Wrocławiu.
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Swiatoniowski
authors.forename: Maria
authors.initials: M
authors.lastname: Dabrowska
authors.forename: Tomasz
authors.initials: T
authors.lastname: Kłaniewski
authors.forename: Włodzimierz
authors.initials: W
authors.lastname: Molenda
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D012307:Risk Factors; D000068878:Trastuzumab; D015854:Up-Regulation
chemical_list: D000903:Antibiotics, Antineoplastic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab